Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some ...

By Amina Niasse (Reuters) -Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up ...

Researchers found that injectable GLP-1 receptor agonists for obesity tended to yield smaller reductions in weight in ...

GLP-1 medications offer promising benefits for obesity and diabetes patients, with studies showing reduced heart attack risk ...

A study, which was published in The New England Journal of Medicine, found that tirzepatide (Zepbound) is more effective for ...

Researchers find tirzepatide more effective than semaglutide for weight loss in a 72-week trial, with significant reductions ...

A clash is brewing between doctors and patients when it comes to treatment for sleep apnea in those with obesity, a new study ...

A study, which was published in The New England Journal of Medicine, found that tirzepatide (Zepbound) is more effective for weight loss in a head-to-head trial with semaglutide (Ozempic ...

Lastly, the researchers observed that while patients who discontinued obesity medications lost significantly less weight ...

These companies own 97% of the weight loss drug market -- which could grow tenfold over the next decade -- and are developing ...

The report also underscored the importance of maintaining muscle mass and bone density while losing weight. Since weight loss ...